Although PARG inhibitors have not yet reached clinical trials, they have shown synergistic effects with CHK1 inhibitors in ovarian cancer cell lines and ovarian PDX models (Pillay et al. 2019). The gene discussed is PARG; the disease is ovarian carcinoma.